artFibro
Financiado
Artifying fibroblasts: Perturbation modelling in the lung tumor phase space to r...
Artifying fibroblasts: Perturbation modelling in the lung tumor phase space to rewire fibroblasts for immunotherapy.
Lung cancer is the leading cause of cancer death. Immunotherapy improved survival rates, but efficacy is limited to selected patients. We recently discovered universal antigen presenting fibroblasts (apFibros) across human and mur...
Lung cancer is the leading cause of cancer death. Immunotherapy improved survival rates, but efficacy is limited to selected patients. We recently discovered universal antigen presenting fibroblasts (apFibros) across human and murine lung tumors and showed that they directly stimulate cancer-specific CD4 T cells, creating immunological hot spots that support immune rejection. These studies achieved a breakthrough on the role of in situ cancer antigen presentation and proposed a novel model whereby tumors can sustain T cells independently of lymph nodes.
Preliminary data suggest that lung apFibros help overcome resistance to checkpoint inhibitors. For their immunotherapeutic exploitation of apFibros two bottlenecks must be overcome: low numbers and incomplete understanding of their configurations. We will integrate computational and laboratory experiments and work in parallel in human and mouse models to generate perturbation datasets across single-cell/cell systems, transcriptomics/epigenomics, spatial/temporal levels, and dissect the molecular landscape that regulates fibroblast states. Our ultimate goal is to unravel perturbations that can diverge cancer-associated fibroblasts to antigen presenting states.
The following questions are at the core of our proposal i) how do diverse fibroblast states emerge and evolve? ii) which gene regulatory networks drive specificity of these states? ii) which are the functional modules that are driven by apFibros and how are they mechanistically explained? iv) how can we transdifferentiate existing fibroblasts to acquire antigen presenting states? v) how can fibroblast reprogramming help overcome immunotherapy resistance?
The proposed research should help advance mechanistic concepts in what we term the adaptive immune mesenchyme, decode the complexity of peripheral antigen presentation in tumors and beyond and promote targeting of the stroma for immunotherapy.
ver más
Duración del proyecto: 60 meses
Fecha Inicio: 2023-03-27
Fecha Fin: 2028-03-31
Fecha Fin: 2028-03-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-27
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-COG:
ERC CONSOLIDATOR GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXA...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5